As more patients with severe cardiovascular disease travel, on-board cardiac events might be expected to increase. A general overview with contraindications to air travel and recommendations for the patient with cardiovascular disease is presented in Tables 1 and 2 . We will review the pathophysiology and delineate the risk for patients with cardiovascular disease of sudden death, DVT, and ischemia/infarction when they travel by air.
On 12 June 2001,the Federal Aviation Administration (FAA) issued a final ruling mandating that passengercarrying aircraft of more than 7,500-lb maximum payload capacity with at least one flight attendant carry at least one automated external defibrillator (AED) and an enhanced emergency medical kit (Table 3 ). All flight attendants will be required to receive initial and recurrent training on AED usage and in cardiopulmonary resuscitation (CPR). The rule becomes effective on 12 April 2004. Page et al. extrapolated from the data accumulated regarding AED use by one major US airline, and suggested that the widespread availability of AEDs on commercial airlines might prevent up to 93 in-flight deaths from ventricular fibrillation each year worldwide. 5 Longterm survival rates in such patients range from 26% to 40%, which compares favorably with the 2% to 5% longterm survival rates often quoted for out-of-hospital arrests. 6, 7 
Pathophysiology: Cardiac Ischemia and Arrhythmias during Air Travel
Air travel impacts on patients with cardiovascular disease in several ways. Patients with cardiovascular disease can be more sensitive to changes in arterial oxygen saturation. Airline cabins are not pressurized to Myocardial infarction within previous 2 weeks Unstable angina Coronary artery bypass graft within previous 2 weeks Poorly compensated heart failure Uncontrolled ventricular or supraventricular arrythmias provide an altitude that mimics sea level. Cabin altitude may vary during an individual flight, although the FAA mandates an effective cabin altitude of 8,000 ft at maximum flying altitude. 8 The effective cabin altitude of a plane flying at 40,000 ft approaches 7,500 ft if the cabin pressure is maintained at 585 mm Hg. 9 The net effect of such pressure changes is to decrease arterial oxygen tension, which could provoke ischemia and arrhythmia in those most susceptible. The arterial oxygen tension in a healthy individual, with a resting PaO 2 of 98 at sea level, may fall to less than 60 mm Hg at such pressures during a routine commercial air flight. 10 One can estimate that inspired PO 2 will fall by 4 mm Hg per 1000 ft above sea level. 10 Patients with concomitant pulmonary disease and even those without pulmonary compromise may require supplemental oxygen during air travel. 10 It is recommended that any passenger with a partial pressure of arterial oxygen of less than 70 mm at sea level at rest should receive supplemental oxygen during air travel. 10 Oxygen should be requested well in advance, and is typically only available at 2-L or 4-L flow rates. Most airlines will also require a letter of medical clearance from the patient's physician at least 48 h prior to the flight. US air carriers will require a prescription for oxygen.Charges for in-flight oxygen vary widely. 11 There are no specific data to support the routine use of in-flight oxygen in travelers who have suffered a recent myocardial infarction (MI) or have cardiac disease.
Several studies have either demonstrated or suggested increased sympathetic activity at altitudes of 1,500 to 3,000 m. 12, 13 This is believed to be secondary to hypoxia at higher altitudes. Angina and ST segment depression have been documented to occur at lower workloads in subjects at high altitude. 12 Whereas one might expect an increase in anginal symptoms during air travel, studies of this patient population during air travel have not been performed. The relative inactivity during air travel may mitigate the decreased work capacity seen at altitude. Similarly, although arrhythmia might be expected to occur more commonly at altitude, given the increased sympathetic activity and increased hypoxia noted above, this has not been borne out in one very small study evaluating the response of elderly subjects to an altitude of 2,500 m. 13 Levine et al. 13 examined the response of 20 subjects with a mean age of 68 years to an altitude of 2,500 m.Two of the 20 had a history of significant arrhythmias. Estimated mean pulmonary artery pressure increased by 43% with acute exposure to altitude, probably secondary to hypoxia and sympathetic activation. No significant arrhythmias were noted in the study group at altitude, although the investigators did find an increase in ventricular premature beats. The very small study size limits the broad application of these results to the air traveler with cardiovascular disease.
The increase in pulmonary artery pressure noted by Levine et al. suggests that travelers with depressed ejection fractions might suffer from increased symptoms of right-or left-sided heart failure during air travel. No study has addressed this issue. Whereas measurement of pulmonary artery pressure during flight might be impractical, a retrospective survey of such patients addressing in-flight symptoms would be relatively easy to undertake.
General Concerns
Dehydration has been a major concern with longhaul air travel, due to the 10% humidity of circulating air on commercial aircraft.Theoretically,dehydration could be expected to contribute to the deleterious effect of air travel on cardiac patients by effectively decreasing preload and therefore cardiac output. Whereas low humidity may lead to dry skin and eye irritation, it has not been proven to result in significant intravascular dehydration. Skjenna et al. cite data demonstrating that most patients actually gain weight secondary to increased fluid intake during air travel. 14 Landgraf et al. simulated flight conditions in 12 healthy volunteers and found an average surplus in fluid balance of 1,100 to 1,200 mL. This corresponded to an average weight gain of approximately 1 kg. 15 Nevertheless, dehydrating alcohol and caffeinated beverages should be avoided, and care should be taken to consume adequate fluids. Airline food is often quite high in sodium. The increased sodium load can present problems for travelers with congestive heart failure, who may be more sensitive to volume shifts than other cardiac patients. Mental stress may lead to cardiac ischemia in those with known coronary artery disease. 16 Flying can be a significant stressor in many travelers, and represents a potential risk factor for in-flight ischemia as well. General recommendations for air travelers with cardiac disease are presented in Table 2 .
Air Travel after Recent Myocardial Infarction
In addition to concern over the risks of ischemia in flight, a number of travelers experience MI while abroad or in close proximity to planned travel. The American Medical Association (AMA) commission on Emergency Medical Services recommended in 1982 that travelers abstain from flying within 3 weeks of an MI. 17 Major advances in angioplasty and coronary revascularization have occurred since the publication of these guidelines and should prompt a re-examination of prior recommendations. The American College of Cardiology recommends a 2-week waiting period prior to travel after an uncomplicated MI. 18 Very few studies have evaluated the safety of air travel following MI. Cox et al. undertook the most extensive examination of the topic in their study of 196 patients with recent MI transported by two medical assistance companies on commercial airliners from December 1986 to October 1989. 19 The majority of patients were men, with a mean age of 63 years. Electrocardiographic localization of the infarction was available for 93% of patients, although peak creatinine kinase values were not provided. Forty-five percent of patients suffered anterior circulation infarctions, whereas 34% of infarcts were localized to the inferior circulation by ECG. Only 4.1% of the patients underwent angioplasty or coronary bypass surgery. Medication data were available for 147 of the 196 study patients. Fifty-six patients were taking aspirin and 32 were taking beta-blockers at the time of transport. Nine patients required physician intervention during the flight. Of these nine, six undertook travel less than 14 days after MI. Cox et al. concluded that air travel may be safely undertaken within 2 to 3 weeks of MI when an accompanying physician is present. 19 Zahger et al. came to a similar conclusion in their small study of 17 patients who suffered acute MI in Israel between May 1996 and May 1999.All patients were risk stratified and offered intervention when appropriate. Seven patients underwent angiography and five were revascularized. Patients flew home 18 Ϯ 11 days after admission. Only five flew with medical escorts, and none of the original 17 patients experienced significant in-flight events. 20 Roby et al. studied 38 patients who chose to fly within a mean 15 to 16 days of acute uncomplicated MI between January 1993 and February 1996. 21 The authors excluded those patients who suffered a complicated infarction defined as the presence of postinfarct angina, arrhythmia, or left ventricular dysfunction lasting for more than several days. Thirty-four of 38 patients had suffered Q-wave infarction, with mean creatinine kinase levels of 866 U/L in the intervention group and 1,217 U/L in the control group. Both groups were accompanied by physician escorts. All patients underwent continuous holter monitoring and oxygen saturation monitoring during flight. The intervention group received 2 L of supplemental oxygen by nasal canula in flight. Only one patient had electrocardiographic evidence of ischemia in flight, whereas five patients had transient oxygen saturation below 90%, and five patients had ventricular ectopy with no episodes of sustained ventricular tachycardia. These data suggest that air travel 2 to 3 weeks after an acute MI is reasonably safe when appropriate revascularization or angiography has been undertaken in highrisk patients. Medical escort may not be necessary. Placement of intracoronary stents should not result in activation of airport security systems. The increasing availability of AEDs on commercial flights may provide an increased measure of security for those who suffer from ventricular fibrillation during air travel. Evaluations of the use of AEDs on board US aircraft show survival rates for resuscitation ranging from 27% to 40%. 
Implantable Cardioverter/Defibrillators and Pacemakers
As implantable pacemaker and implantable cardioverter/defibrillator (ICD) technology has advanced, a substantial percentage of patients with cardiac disease have undergone the implantation of such devices. Many pacemakers and ICDs can be interrogated and adjusted externally via a wireless communications link. Magnets producing a strong enough field will inhibit tachycardia therapy when placed on top of almost all ICD models while the magnet is in place. 22 These features present several potential problems for those wishing to travel by air. The major manufacturers of pacemaker and ICD technology assert that their devices will not be harmed by airport security systems, although they caution that either device may be temporarily affected.
Both ICDs and pacemakers may, in rare cases, set off airport metal detectors. 23 All patients should carry a card from a physician or the manufacturer of the device. Pacemakers and ICDs may, theoretically, undergo temporary malfunction when exposed to airport metal detection equipment, but the few published studies have not shown significant interference with device function. [24] [25] [26] Cooperman et al. studied the effect of metal detector gates on 103 pacemaker patients in Israel. 24 Patients were monitored with telemetry as they passed through the detector. No pacemaker dysfunction was observed in this small sample. Kattenbeck et al. studied the interaction between metal detectors and ICDs in 45 patients. 25 Each patient walked through an airport metal detector gate and was subjected to testing with a hand-held metal detector. Each ICD was interrogated prior to and following exposure to both systems. No changes in ICD parameters were observed, although the alternating magnetic field of a hand-held metal detector would not be expected to alter ICD parameters. The study did not evaluate ICD function or parameters while the individuals were exposed to the two systems. 25 Kolb et al. exposed 200 patients with implanted pacemakers and 148 patients with ICDs to a standard airport metal detector gate. 26 Patients remained within the electromagnetic field of the metal detector gate for at least 20 s. All devices were interrogated before and after exposure. An external six-lead electrocardiogram was recorded during exposure. No change in parameters, inappropriate detection of nonsustained ventricular arrhythmias or suspension of therapies was observed. 26 Although the major manufacturers of ICD technology have not received any reports of delivery of ICD therapy due to exposure to hand-held metal detectors, there is a theoretical risk that the alternating magnetic field created by the hand-held wand might be detected by the device and lead to delivery of inadvertent shock therapy and/or temporarily inhibit an ICD's pacemaker output. The FAA has yet to publish specific guidelines on this issue. The National Institute of Justice currently requires that all hand-held metal detectors carry a warning that they may interfere with personal medical electronic devices. 27 It is therefore advised that patients with ICDs do not allow a search with a hand-held device and instead request a hand search. If a hand-held device must be used, the examiner should be cautioned not to hold the magnet over the device for more than a few seconds. If a hand-held wand must be passed over the device more than once, at least 30 s should elapse between each pass. Neither ICDs nor pacemakers should be affected by the Patients with ICDs may be shocked with an AED if their device fails while in flight, although device failure is no more common during air travel than at other times. All patients with implantable devices should carry an ID card detailing the type of device, their physician's contact information and the date of implantation. It is also advised that patients carry a copy of an ECG taken with and without pacing. A summary of recommendations and resources for the traveler with implanted devices is given in Table 4 .
Pulmonary Embolism and Deep Venous Thromboembolism during Air Travel
DVT and thromboembolism have long been proposed as possible complications of air travel. Pulmonary embolism (PE) has been suggested as a culprit in deaths related to air travel, although evidence linking air travel to DVT has been somewhat elusive. [28] [29] [30] Sarvesvaran found that 18% of sudden deaths among long-distance travelers over a 3-year period at Heathrow were attributable to PE. 28 Lapostolle et al. recently described 56 cases of PE discovered at Charles de Gaulle Airport from 1993 to 2000. 30 They found that distance traveled was a significant risk factor for the development of PE, with those who traveled over 5,000 km being at the highest risk. 30 Perez-Rodriguez et al. documented an incidence of 1.65 PEs per million in passengers traveling for more than 8 h between January 1995 and December 2000 at MadridBarajas airport. 31 Scurr et al. demonstrated that the risk of symptomless calf DVT was as high as 10% in subjects over 50 years of age on flights longer than 8 h. 32 Subjects with cardiorespiratory disease, however, were excluded from the study population. Schwarz et al. found a somewhat lower risk of isolated calf venous thrombosis in a population of 964 travelers flying for an average of 8 h or more: 33 2.1% of travelers vs. 0.8% of controls were diagnosed with symptomless calf venous thrombosis. The rate of DVT in the traveling cohort was 0.7%, compared to The Lonflit 1 study was planned to evaluate the incidence of DVT as a consequence of long fights in economy class. DVT diagnosis was made by comparing ultrasound scans 48 h before flying and 24 h after flying. 35 The study evaluated 355 subjects at low risk for DVT and 389 at high risk, defined as prior DVT, malignancy within 2 years, limited mobility, coagulation disorders or large varicose veins. 35 Subjects with artificial cardiac valves, diabetes, hypertension, renal or hepatic insufficiency and pacemakers were excluded. 35 No DVTs were found in the low-risk group, whereas 2.8% of the high-risk group were found to have evidence of new thrombosis after an average of 12.4 h of flying; almost all cases (94.7%) were observed in subjects sitting in window or central seats. The putative mechanisms of increased risk during air travel include venous stasis, fluid retention, hemoconcentration secondary to dehydration, and increased erythropoietin levels. 36 Decreased PaO 2 may also play a role by interfering with fibrinolysis and activating the coagulation cascade. 37, 38 Congestive heart failure has long been proposed as a risk factor for venous thromboembolism (VTE). Chronic hypercoagulability and venous stasis have both been proposed as possible mechanisms. Howell et al. found that a left ventricular ejection fraction (LVEF) between 20% and 44% was associated with an increased risk of VTE, with an odds ratio of 2.8 (95% CI 1.4-5.7%) in a population of Veteran's administration patients. 39 LVEF Ͻ 20% was associated with an odds ratio of 38.3 (95% CI 9.6-152.5%) for VTE. 39 Although it has been difficult to draw significant conclusions regarding the prevalence of DVT and PE secondary to air travel, compression stockings have been proven to decrease the incidence of calf DVT and may decrease the overall risk of more proximal DVT and PE. Scurr et al. presented compelling evidence that superficial calf DVT may be prevented by the use of graduated elastic compression stockings. 32 The selection criteria excluded patients with cardiorespiratory disease, malignancy, and prior venous thrombosis. All subjects were over 50 years of age. None of the 115 patients who wore compression stockings were found to have calf DVTs after flights of more than 8 h. 32 The Lonflit 4 trial provided further evidence of the efficacy of compression stockings in the prevention of lower extremity venous thrombosis in low-to medium-risk patients. 40 No lower extremity venous thromboses were detected among 184 subjects in the group randomized to compression stockings, whereas four deep venous thromboses and two superficial thromboses were discovered in the control group of 188 patients. All subjects traveled for 7 to 8 h by air in economy class. The Lonflit 2 trial supports the use of compression stockings in populations at high risk for DVT. 35 In Lonflit 2, 833 subjects believed to be at high risk for DVT based on prior DVT, coagulation disorders, neoplastic disease, large varicose veins or limited mobility were prospectively randomized to below-the-knee compression stockings or no intervention during air travel lasting for an average of 12.4 h. Twenty-two DVTs were identified in 19 of the 422 subjects in the control group, whereas only one DVT was found in the 411 subjects who wore below-the-knee elastic compression stockings. 35 In both groups, all subjects were seated in window or central seats.
The role of aspirin therapy in the prevention of VTE has been a subject of considerable debate. The most recent guidelines from the American College of Chest Physicians do not recommend the use of aspirin as prophylaxis for venous thrombosis, although the guidelines do not specifically address the issue of air travel and venous thrombosis. 41 The authors cite the superior efficacy of other agents, notably low-molecular-weight heparin (LMWH), unfractionated heparin and warfarin, in making their recommendations. The prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial randomized 13,356 patients undergoing surgery for hip fracture and 4,088 patients undergoing elective arthroplasty to 160 mg daily aspirin therapy or placebo started preoperatively and continued for 35 days. 42 The use of other thromboprophylactic measures was permitted. Eighteen percent of patients were treated with unfractionated heparin, 26% with LMWH, and 30% with thromboembolic-deterrent stockings. Aspirin therapy reduced the risk of PE and DVT by 34% in the combined groups, with a similar proportional risk reduction in those treated with heparin. In those patients taking aspirin alone vs. placebo, the risk of bleeding was 2.6% vs. 2.5%. The concomitant use of other thromboprophylaxis and the high-risk nature of the patient population make any extrapolation to other populations quite difficult.
Lonflit 3 evaluated the efficacy of aspirin and LMWH in the prevention of DVT in 300 high-risk subjects traveling for more than 10 h by air. 43 Patients were defined as high risk if they had had prior DVT, a coagulation disorder,obesity or severely limited mobility,malignancy within the preceding 2 years,or large varicose veins.Patients with cardiovascular disease, diabetes and hypertension were excluded.The control group received no intervention.The aspirin group received 400 mg of aspirin daily for 3 days, beginning 12 h before the start of air travel. The LMWH group received one dose of enoxaparin 2 to 4 h prior to the flight, based on a weight-adjusted protocol. Six DVTs were discovered in the control group involving four patients, whereas three DVTs involving three patients were found in the aspirin arm. The p-value for number of limbs involved was Ͻ .05,but was not statistically significant when the number of patients with DVT was analyzed.No DVTs were identified in the enoxaparin arm. The p-value was Ͻ .002 for limbs affected when compared to controls.The statistical significance of enoxaparin compared to aspirin was not given. It is difficult to make inferences for either the population in question or air travelers as a whole based on this study. The small size of the study, the small number of patients with DVT and the lack of statistical significance when numbers of patients with DVT are compared in the aspirin and placebo groups do not allow justification of aspirin therapy in this group. The PEP trial would support the use of a 160-mg dose rather than 400 mg in any subsequent study.The use of LMWH has been shown to be efficacious in the prevention of DVT in high-risk populations and is recommended for DVT prophylaxis in high-risk postoperative patients. 41 Lonflit 3 supports the utility of LMWH in high-risk populations during air travel.
Compression stockings appear to represent a reasonable measure in all travelers over the age of 50 years who fly for more than 8 h or further than 5,000 km in a single journey. Whereas Lonflit 3 excluded patients with cardiovascular disease, many travelers with cardiac disease will be on chronic aspirin therapy prior to embarking on air travel. The appropriate dose of aspirin and its specific role in this population remain unclear. Lonflit 3 suggests that aspirin would not be of great utility in a moderate-risk population, as it did not significantly alter the incidence of DVT in a high-risk population. A retrospective trial analyzing the incidence of symptomatic DVT and PE in patients on chronic aspirin therapy would require a large number of patients, but is quite feasible. LMWH may prove useful in patients at particularly high risk for DVT who are not maintained on chronic anticoagulation. Avoidance of constrictive clothing, avoidance of leg crossing and participation in minor physical activity during flights are likely to have some efficacy as well, although this has not been proven. Aisle seating, avoidance of tobacco and alcohol-containing beverages, and increased consumption of fluids may also be of benefit. Based on the best available evidence, we recommend a risk stratification system for travelers with cardiac disease and prophylactic measures to prevent thromboembolism in Table 5 . Future randomized prospective trials identifying high-risk patients who may require anticoagulation are needed in travelers with cardiac disease.
Conclusions
The number of air travelers with cardiac disease will continue to increase. Advances in pacemaker, AICD and revascularization will allow many who could not travel only a few decades ago to do so with relative ease. This growing population will face a variety of hazards related to air travel, including in-flight ischemia, arrythmia, and venous thromboembolic events. Although there is a dearth of research specifically examining the air traveler with cardiac disease, we have attempted to provide a set of guidelines based on available evidence and basic pathophysiology. These guidelines should not substitute for cardiologic consultation when warranted.
Future research is needed to further assess the risk of air travel after MI in the age of more complete revascularization and more aggressive antiplatelet therapy. None of the trials cited discuss the use of glycoprotein IIb/IIIa inhibitors, clopidogrel, or drug-coated stents. AMA guidelines on this topic may require revision based on these advances. The current generation of pacemakers and ICDs would allow easy access to data regarding inflight arrhythmia and might help to further elucidate the impact of altitude on the occurrence of ventricular and atrial arrhythmias. The increasing availability of AEDs will provide further data regarding the incidence of cardiac arrest as a cause of in-flight medical events and in-flight death. N.B. It should be noted that these recommendations are based on the best available evidence. To date, only one randomized trial has evaluated the use of aspirin and low-molecularweight heparin in high-risk populations.
Modified from Ferrari et al., 29 House of Lords Select Committee on Science and Technology, 47 and Cesarone et al. 43 LVEF, left ventricular ejection fraction. 
